CDX2 and colorectal carcinoma: GSK126 is effective in inhibiting CRC cell invasion in combination with an farnesoid X receptor (FXR) agonist (obeticholic acid) in a virtually side-effect-free manner, a process that is dependent on activation of caudal type homeobox 2 expression and accelerated nuclear localization of FXR.